Adding radiotherapy to standard hormone therapy helps patients with prostate cancer with limited spread of the disease, to live longer. This result from the STAMPEDE trial was published, in open access format, in the PLOS Medicine journal, in early June. For more on this story, please click on the following link to the UCL News feed: https://www.mrcctu.ucl.ac.uk/news/news-stories/2022/june/adding-radiotherapy-can-benefit-some-patients-whose-prostate-cancer-has-spread/ ...
STAMPEDE Trial Further Results - Adding Radiotherapy Can Benefit Some Patients Whose Prostate Cancer Has Spread
STAMPEDE Five Year Follow-up Results
A five year follow-up of the STAMPEDE abiraterone comparison has been completed, and the results demonstrate that previously reported effects are robust. It shows that future results are unlikely to change meaningfully with further follow-up. The initial results of the STAMPEDE advanced prostate cancer trial showed that progression-free survival is improved when abiraterone acetate and prednisone (AAP) are added to androgen deprivation therapy. For further details related to the follow-up results, please see this article published 12th April 2022 - https://onlinelibrary.wiley.com/doi/10.1002/ijc.34018 ...
STAMPEDE Radiotherapy Results Films
Treating the prostate with radiotherapy alongside standard treatment substantially improves survival for some men with advanced prostate cancer, according to results from the STAMPEDE trial, published in The Lancet and presented at the 2018 ESMO Annual Meeting in Munich in October 2018. If you missed it, you can read the full news story from the time here. We are now delighted to share these new films that explore the results: Full version: Short version: ...
Prostate radiotherapy can benefit some men whose cancer has spread
Treating the prostate with radiotherapy alongside standard treatment substantially improves survival for some men with advanced prostate cancer, according to results from the STAMPEDE trial, published in The Lancet and presented at the 2018 ESMO Annual Meeting in Munich, Germany yesterday. These findings are practice changing and will mean radiotherapy, alongside hormone therapy should become the standard of care for some men with advanced prostate cancer. In this part of the STAMPEDE trial, more than 2,000 men with prostate cancer that had already spread beyond the prostate were randomly split into two groups: Group A received standard treatment (hormone therapy, plus docetaxel for those men who were recruited in 2016) Group H received standard treatment (hormone therapy, plus docetaxel for those men who were recruited in 2016) plus radiotherapy to their prostate. After three years of follow-up, the researchers found that overall, there was no difference in how long men ...
SCT Clinical Trial of the Year
The STAMPEDE trial has received the '2017 David Sackett Trial of the Year Award' from the Society for Clinical Trials (SCT). Each year since 2008, the SCT has presented the award to the randomized clinical trial published in the previous year that best fulfils exacting standards. The trial must provide the basis for a substantial, beneficial change in healthcare, reflect expertise, methodological excellence, and concern for its participants. The trial's design, execution, and results must be a model of clarity and intellectual soundness. The international award was presented at the 39th SCT Annual Meeting held 20-23 May 2018, in Portland, Oregon. Professor Mahesh Parmar, Director of MRC CTU at UCL and the UCL Institute of Clinical Trials and Methodology, accepted the award on behalf of the STAMPEDE trial team. Professor Parmar said: "The STAMPEDE trial's innovative design allows us to achieve answers to questions decades before the more traditional sequential two-arm trial approac ...
MRC Clinical Trials Unit at UCL
90 High Holborn